Mycobacterial HSP70 as an adjuvant in the design of an idiotype vaccine against a murine lymphoma

Cellular Immunology

Volumn 254, Issue 1, 2008, Pages 74-80

  Karyampudi, Lavakumar ^a   Ghosh, Swapan K ^a  

^a INDIANA STATE UNIVERSITY   (United States)

Author keywords

B cell lymphoma; Cytotoxic T cell (CTL) response; Idiotype; Mycobacterial HSP70; Recombinant fusion protein

Indexed keywords

ADJUVANT; ANTIBODY CONJUGATE; CYTOKINE; GAMMA INTERFERON; HEAT SHOCK PROTEIN 70; HYBRID PROTEIN; IMMUNOGLOBULIN G2A; IMMUNOGLOBULIN IDIOTYPE; RECOMBINANT PROTEIN; RECOMBINANT PROTEIN H; RECOMBINANT PROTEIN SCFV; RECOMBINANT PROTEIN SCFV H; UNCLASSIFIED DRUG; VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B CELL LYMPHOMA; CANCER MORTALITY; CELL ACTIVITY; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; EXPRESSION VECTOR; FEMALE; IMMUNOGENICITY; MALE; MOUSE; MYCOBACTERIUM; NONHUMAN; PLASMID; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PURIFICATION; PROTEIN SECRETION; SURVIVAL RATE; TUMOR IMMUNITY; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; ANTIGENS, NEOPLASM; CANCER VACCINES; CELL LINE, TUMOR; ENZYME-LINKED IMMUNOSORBENT ASSAY; HSP70 HEAT-SHOCK PROTEINS; IMMUNOGLOBULIN IDIOTYPES; LYMPHOMA; MICE; MICE, INBRED BALB C; MYCOBACTERIUM; RECOMBINANT FUSION PROTEINS;

MURINAE; MUS;

EID: 55049111086     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2008.07.003     Document Type: Article

References (41)

1. George A.J.T., and Stevenson F.K. Prospect for the treatment of B cell tumors using idiotypic vaccination. Int. Rev. Immunol. 4 (1989) 271-310
2. Stevenson F.K., Zhu D., King C.A., Ashworth L.J., Kumar S., and Hawkins R.E. Idiotypic DNA vaccines against B-cell lymphoma. Immunol. Rev. 145 (1995) 211-228
3. Kaminski M.S., Kimatura K., Maloney D.G., and Levy R. Idiotypic vaccination against a murine B-cell lymphoma: inhibition of tumor immunity by free idiotypic protein. J. Immunol. 138 (1987) 1289-1296
4. Chen T.T., Tao M.H., and Levy R. Idiotype-cytokine fusion proteins as cancer vaccines. Relative efficacy of IL-2, IL-4, and granulocyte-macrophage colony-stimulating factor. J. Immunol. 153 (1994) 4775-4787
5. Tao M.H., and Levy R. Idiotype/granulocyte-macrophage colony-stimulating factor fusion protein as a vaccine for B-cell lymphoma. Nature 362 (1993) 755-758
6. King C.A., Spellerberg M.B., Zhu D., Rice J., Sahota S.S., Thompsett A.R., Hamblin T.J., Radl J., and Stevenson F.K. DNA vaccines with single-chain Fv fused to fragment C of tetanus toxin induce protective immunity against lymphoma and myeloma. Nat. Med. 4 (1998) 1281-1286
7. Timmerman J.M., Czerwinski D.K., Davis T.A., Hsu F.J., Benike C., Hao Z.M., Taidi B., Rajapaksa R., Caspar C.B., Okada C.Y., Beckhoven A., Liles T.M., Engleman E.G., and Levy R. Idiotype-pulsed dendritic cell vaccination for B-cell lymphoma: clinical and immune responses in 35 patients. Blood 99 (2002) 1517-1526
8. Kwak L.W., Young H.A., Pennington R.W., and Weeks S.D. Vaccination with syngeneic, lymphoma-derived immunoglobulin idiotype combined with granulocyte/macrophage colony-stimulating factor primes mice for a protective T-cell response. Proc. Natl. Acad. Sci. USA 93 (1996) 10972-10977
9. Huang H.I., Wu P.Y., Teo C.Y., Chen M.N., Chen Y.C., Silin D., and Tao M.H. Improved immunogenicity of self tumor antigen by covalent linkage to CD40 ligand. Int. J. Cancer 108 (2004) 696-703
10. Armstrong A.C., Dermime S., Allinson C.G., Bhattacharyya T., Mulryan K., Gonzalez K.R., Stern P.L., and Hawkins R.E. Immunization with a recombinant adenovirus encoding a lymphoma idiotype: induction of tumor-protective immunity and identification of an idiotype-specific T cell epitope. J. Immunol. 168 (2002) 3983-3991
11. Caspar C.B., Levy S., and Levy R. Idiotype vaccines for non-hodgkin's lymphoma induce polyclonal immune responses that cover mutated tumor idiotypes: comparison of different vaccine formulations. Blood 90 (1997) 3699-3706
12. Bogen B., Jorgensen T., and Hannestad K. T helper cell recognition of idiotopes on lambda 2 light chains of M315 and T952: evidence for dependence on somatic mutations in the third hypervariable region. Eur. J. Immunol. 15 (1985) 278-281
13. Biragyn A., Tani K., Grimm M.C., Weeks S., and Kwak L.W. Genetic fusion of chemokines to a self tumor antigen induces protective, T-cell dependent antitumor immunity. Nat. Biotechnol. 17 (1999) 253-258
14. Reichardt V.L., Okada C.Y., Liso A., Benike C.J., Stockerl-Goldstein K.E., Engleman E.G., Blume K.G., and Levy R. Idiotype vaccination using dendritic cells after autologous peripheral blood stem cell transplantation for multiple myeloma-a feasibility study. Blood 93 (1999) 2411-2419
15. Park H.J., and Neelapu S.S. Developing idiotype vaccines for lymphoma: from preclinical studies to phase III clinical trials. Br. J. Haematol. 13 April (2008) epub ahead of print
16. Wallin R.P., Lundqvist A., More S.H., von Bonin A., Kiessling R., and Ljunggren H.G. Heat shock proteins as activators of the innate immune system. Trends Immunol. 23 (2002) 130-135
17. Parmiani G., Testori A., Maio M., Castelli C., Rivoltini L., Pilla L., Belli F., Mazzaferro V., Coppa J., Patuzzo R., Sertoli M.R., Hoos A., Srivastava P.K., and Santinami M. Heat shock proteins and their use as anticancer vaccines. Clin. Cancer Res. 10 (2004) 8142-8146
18. Suzue K., and Young R.A. Adjuvant-free hsp70 fusion protein system elicits humoral and cellular immune responses to HIV-1 p24. J. Immunol. 156 (1996) 873-879
19. Udono H., Yamano T., Kawabata Y., Ueda M., and Yui K. Generation of cytotoxic T lymphocytes by MHC class I ligands fused to heat shock cognate protein 70. Int. Immunol. 13 (2001) 1233-1242
20. Suzue K., Zhou X., Eisen H.N., and Young R.A. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc. Natl. Acad. Sci. USA 94 (1997) 13146-13151
21. Palliser D., Huang Q., Hacohen N., Lamontagne S.P., Guillen E., Young R.A., and Eisen H.N. A role of Toll-like receptor 4 in dendritic cell activation and cytolytic CD8+ T cell differentiation in response to a recombinant heat shock fusion protein. J. Immunol. 172 (2004) 2885-2893
22. Castellino F., Boucher P.E., Eichelberg K., Mayhew M., Rothman J.E., Houghton A.N., and Germain R.N. Receptor-mediated uptake of antigen/heat shock protein complexes results in major histocompatibility complex class I antigen presentation via two distinct processing pathways. J. Exp. Med. 191 (2000) 1957-1964
23. Cho B.K., Palliser D., Guillen E., Wisniewski J., Young R.A., Chen J., and Eisen H.N. A proposed mechanism for the induction of cytotoxic T lymphocyte production by heat shock fusion proteins. Immunity 12 (2000) 263-272
24. Garner M.W., Raymond A., Akporiaye E., and Katsanis E. Tumor-derived multiple chaperone enrichment by free-solution isoelectric focusing yields potent anti tumor vaccines. Cancer Immunol. Immunother. 49 (2000) 476-484
25. Garner M.W., Zeng Y., Feng H., and Katsanis E. Tumor derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol. Immunother. 52 (2003) 226-234
26. Ciupitu A.M., Petersson M., Kono K., Charo J., and Kiessling R. Immunization with heat shock protein 70 from methylchloanthrene-induced sarcomas induces tumor protection correlating with in vitro T cell responses. Cancer Immunol. Immunother. 51 (2002) 163-170
27. Kim K.J., Langevin C.K., Merwin R.M., Sachs D.H., and Asofsky R. Establishment and characterization of BALB/c lymphoma lines with B cell properties. J. Immunol. 122 (1979) 549-554
28. Al-shaibi N., and Ghosh S.K. A novel phosphoprotein is induced during bone marrow commitment to dendritic cells. Biochem. Biophys. Res. Commun. 321 (2004) 26-30
29. Laxmanan S., Stuart G., and Ghosh S.K. A stable single-chain variable fragment expressing transfectoma demonstrates induction of idiotype-specific cytotoxic T cells during early stages of B-cell tumor progression. Cancer Immunol. Immunther. 50 (2001) 437-444
30. Santra S., and Ghosh S.K. Interleukin-4 is effective in restoring cytotoxic T cell activity that declines in vivo progression of a murine B lymphoma. Cancer Immunol. Immunother. 44 (1997) 291-300
31. Liso A., Benedetti R., Fagioli M., Matiano A., and Falini B. Modulatory effects of mycobacterial heat-shock protein 70 in DNA vaccination against lymphoma. Haematologica 90 (2005) 60-65
32. Chakrabarti D., and Ghosh S.K. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. I. Role of idiotypic immunoglobulin. Cell. Immunol. 142 (1992) 54-66
33. Chakrabarti D., and Ghosh S.K. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. II. Characterization of anti-idiotypic CTL lines and clones. Cell. Immunol. 144 (1992) 443-454
34. Chakrabarti D., and Ghosh S.K. Induction of syngeneic cytotoxic T lymphocytes against a B cell tumor. III. MHC class I-Restricted CTL recognizes the processed form(s) of idiotype. Cell. Immunol. 144 (1992) 455-464
35. Syrengelas A.D., and Levy R. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection. J. Immunol. 162 (1999) 4790-4795
36. Fredriksen A.B., Sandlie I., and Bogen B. DNA vaccines increase immunogenicity of idiotypic tumor antigen by targeting novel fusion proteins to antigen-presenting cells. Mol. Ther. 13 (2006) 776-784
37. George A.J., Spellerberg M.B., and Stevenson F.K. Idiotype vaccination leads to the emergence of a stable surface Ig-negative variant of the mouse lymphoma BCL, with different characteristics. J. Immunol. 140 (1988) 1695-1701
38. Meeker T., Lowder J., Cleary M.L., Stewart S., Warnke R., Sklar J., and Levy R. Emergence of idiotype variants during treatment of B cell lymphoma with anti-idiotypic antibodies. N. Engl. J. Med. 312 (1985) 1658-1665
39. Ghosh S.K., and Bankert R.B. Generation of heavy chain loss mutants in a B cell hybrid mediated by syngeneic idiotype-specific spleen cells. J. Immunol. 133 (1984) 1677-1682
40. Ghosh S.K., Wong J., and Bankert R.B. Idiotype-specific T lymphocytes responsible for selection of somatic variants of a B cell hybrid. J. Immunol. 138 (1987) 2230-2235
41. J.M. Timmerman, Vaccines for treating cancer, World Intellectual Property Organization, Patent Pub no. WO/2007/106435, September 20, 2007.